[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products

Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease 5%, driven by lower demand for COVID-19 products and a base effect from a patent settlement in 2022;IFRS net incomedown 9% due to lower core operating profit and higher interest expensesHighlightsin the second quarter of 2023:US and EU approvals ofColumvi (aggressive form of blood cancer)US approval ofElevidys for Roche partner Sarepta (first gene therapy for children with Duchenne muscular dystrophy)Positive phase III data for subcutaneous injection ofOcrevus (multiple sclerosis); positive long-term efficacy and safety data forEvrysdi (spinal muscular atrophy) and positive phase II data forfenebrutinib (multiple sclerosis)Start of phase III study oftiragolumab in combination with Tecentriq and Avastin (liver cancer)Partnership withAlnylam to co-develop phase II RNAi therapeuticzilebesiran (hypertension in patients with high cardiovascular risk)WHO prequalification ofcobas HPV...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news